Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

515
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
515
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

159
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
159
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

570
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
570

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Postoperative dietary management after parotid gland surgery in the absence of high-level evidence: consensus-based guidelines and a stepwise protocol for diet advancement.

Frontiers in surgery·2026
Same authorSame journal

The "engine room" of a multicentre geriatric otolaryngology network: data curation, quality assurance, and research readiness of the ENT Geriatric Database.

Otolaryngologia polska = The Polish otolaryngology·2026
Same author

Editorial: 10th anniversary of frontiers in surgery: celebrating progress and envisioning the future of multidisciplinary surgery.

Frontiers in surgery·2026
Same authorSame journal

Diagnostic Accuracy of Fine-Needle Aspiration Cytology in Salivary Gland Tumors: A 1331-Patient Multicenter Analysis of Institutional Variability and Size-Dependent Pitfalls.

Otolaryngologia polska = The Polish otolaryngology·2026
Same author

Neuroimmune Mechanisms in Equine Asthma: Primary Inflammatory Triggers, Neuroimmune Modulation and Chronic Airway Remodelling.

Animals : an open access journal from MDPI·2026
Same author

Longitudinal Voice Handicap in Adult Recurrent Respiratory Papillomatosis Under Stepwise Treatment.

Journal of voice : official journal of the Voice Foundation·2026

Related Experiment Video

Updated: Jun 25, 2025

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
09:52

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

9.4K

Ototoxicity in Immune Checkpoint Inhibitors Therapy.

Małgorzata Wierzbicka1, Jarosław Mielnik2, Ewelina Kołodziejska2

  • 1Regional Specialist Hospital Wroclaw, Research & Development Centre, Wroclaw, Poland, Faculty of Medicine Wroclaw University of Science and Technology, Wroclaw, Poland.

Otolaryngologia Polska = the Polish Otolaryngology
|May 29, 2024
PubMed
Summary
This summary is machine-generated.

Immune checkpoint inhibitors (ICIs) can cause hearing loss, tinnitus, and balance issues. Most ICI-related hearing loss cases reviewed were reversible, highlighting the need for management strategies.

Keywords:
ICIhearing lossimmune-related adverse eventsototoxicity

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

325
The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration
12:21

The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration

Published on: November 26, 2015

17.4K

Related Experiment Videos

Last Updated: Jun 25, 2025

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
09:52

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

9.4K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

325
The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration
12:21

The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration

Published on: November 26, 2015

17.4K

Area of Science:

  • Oncology
  • Immunology
  • Ototoxicology

Background:

  • Immune checkpoint inhibitors (ICIs) are a cornerstone of modern cancer therapy.
  • Treatment-related toxicities, known as immune-related adverse events (irAEs), are emerging complications of ICIs.
  • Ototoxicity, including hearing loss, tinnitus, and balance disorders, is a significant irAE impacting patient quality of life.

Purpose of the Study:

  • To conduct a comprehensive literature review on the ototoxicity associated with immune checkpoint inhibitors (ICIs).

Main Methods:

  • A systematic literature search was performed across Web of Science, PubMed, and Embase databases.
  • Studies published up to March 1, 2022, were included in the review.

Main Results:

  • Reported symptoms included sudden bilateral hearing loss, imbalance, and tinnitus.
  • The median time to hearing loss onset after ICI initiation was 3 months.
  • Over 60% of cases involved bilateral sensorineural hearing loss, often accompanied by other irAEs; 45.7% of patients experienced significant hearing improvement.

Conclusions:

  • The majority of ICI-related hearing loss cases identified in the literature demonstrated reversibility.
  • Developing and implementing standardized therapeutic algorithms for ICI-induced ototoxicity is crucial.
  • Further research is required to determine the precise prevalence, optimal diagnostic approaches, and management strategies for ICI-related hearing loss.